...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: The therapeutic potential of BRD4 in cardiovascular disease

Paid access to the full article, but I do know there are at least 3 references to Apabetalone/RVX 208:

 

36.

Gilham D, Tsujikawa LM, Sarsons CD, Halliday C, Wasiak S, Stotz SC, et al. Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis 2019;280:75–84

76.

Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA 2013;110:19754–9.    ...and

77.

Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis 2014;236:91–100.

Share
New Message
Please login to post a reply